熱門資訊> 正文

Biohaven非GAAP每股收益为-3.50美元，落后1.80美元

2024-08-09 15:26

Biohaven press release (NYSE:BHVN): Q2 Non-GAAP EPS of -$3.50 misses by $1.80.
Cash, cash equivalents, marketable securities and restricted cash totaled approximately $440 million on June 30, 2024.

More on Biohaven

Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment
Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge
Morgan Stanley starts Biohaven at overweight, cites broad pipeline
Biohaven stock falls 30% premarket amid drug updates
Seeking Alpha’s Quant Rating on Biohaven

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。